【BioSpark RoundTable】Drug development reflection - What If Phase 1 Was Enough?

​On May 17, 2025, Montana State announced a groundbreaking policy shift: drugs can now be commercialized after Phase 1 trials, bypassing traditional Phase 2 and 3 requirements. Wild idea, right? Or maybe it’s the start of something? Whether this becomes a blueprint or an outlier, it invites us to reimagine the foundations of drug development.

​At this closed-door discussion, we’ll bring together drug developers, biotech builders, and policy thinkers to explore this potential paradigm shift: What if drug development actually did stop after Phase 1? What opportunities would that open up? What risks would explode? And what frameworks—regulatory, financial, ethical—would be needed to make such a system even even minimally viable?

​This is not a debate, but a mind-stretching exercise in future thinking. Bring your sharpest questions, wildest ideas, and an open mind. Let’s stretch the edges of what drug development could look like.

​Biotech folks, thinkers, and skeptics welcome.